ANIP Key Statistics, Chart & Performance
The current stock price of ANIP is 82.41 USD. In the past month the price decreased by -2.31%. In the past year, price increased by 51.46%.
ANIP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About ANIP
Company Profile
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Company Info
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 897
Phone: 12186343500
ANI PHARMACEUTICALS INC / ANIP FAQ
What does ANIP do?
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
What is the stock price of ANI PHARMACEUTICALS INC today?
The current stock price of ANIP is 82.41 USD. The price increased by 0.28% in the last trading session.
What is the dividend status of ANI PHARMACEUTICALS INC?
ANIP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANIP stock?
ANIP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is ANI PHARMACEUTICALS INC (ANIP) stock traded?
ANIP stock is listed on the Nasdaq exchange.
What is the employee count for ANIP stock?
ANI PHARMACEUTICALS INC (ANIP) currently has 897 employees.
What is the market capitalization of ANIP stock?
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.85B USD. This makes ANIP a Small Cap stock.
ANIP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP is one of the better performing stocks in the market, outperforming 83.51% of all stocks.
ANIP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ANIP. ANIP has only an average score on both its financial health and profitability.
ANIP Financial Highlights
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 7.17. The EPS increased by 56.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.13% | ||
| ROA | 2.42% | ||
| ROE | 6.75% | ||
| Debt/Equity | 1.2 |
ANIP Forecast & Estimates
14 analysts have analysed ANIP and the average price target is 111.33 USD. This implies a price increase of 35.09% is expected in the next year compared to the current price of 82.41.
For the next year, analysts expect an EPS growth of 46.08% and a revenue growth 44.16% for ANIP